Contraceptive devices: subcutaneous delivery systems
暂无分享,去创建一个
[1] E. Coutinho,et al. Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women. , 1999, Contraception.
[2] H. Croxatto,et al. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. , 1983, Contraception.
[3] F. Kincl,et al. Sustained release hormonal preparations. 1. Diffusion of various steroids through polymer membranes. , 1968, Steroids.
[4] A. Biswas,et al. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids--a randomized comparative study. , 2003, Contraception.
[5] D. Wise,et al. An injectable sustained release fertility control system. , 1976, Contraception.
[6] E R Garrett,et al. Evaluation, control, and prediction of drug diffusion through polymeric membranes. II. Diffusion of aminophenones through silastic membranes: a test of the pH-partition hypothesis. , 1968, Journal of pharmaceutical sciences.
[7] I. Fraser,et al. Norplant consensus statement and background review. , 1998, Contraception.
[8] S. Monroe,et al. Clinical evaluation of the Capronor contraceptive implant: preliminary report. , 1989, American journal of obstetrics and gynecology.
[9] P. Dziuk,et al. Passage of steroids through silicone rubber. , 1966, Endocrinology.
[10] D. Mishell,et al. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants. , 1997, Contraception.
[11] E. Diczfalusy,et al. Hormonal effects of the 300 μg norethisterone (NET) minipill , 1979 .
[12] D. Mishell,et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. , 1997, Contraception.
[13] E. Diczfalusy,et al. Hormonal effects of the 300 microgram norethisterone (NET) minipill. 3. Comparison of the short-term (2nd month) and medium-term (6th month) effects in 21 subjects. , 1981, Contraception.
[14] H. Nash,et al. Release of contraceptive steroids from sustained release dosage forms and resulting plasma levels. , 1978, Contraception.
[15] L. Bahamondes,et al. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. , 2004, Contraception.
[16] A. Faúndes,et al. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants. , 1985, Contraception.
[17] G. Benagiano,et al. Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 1. Diffusion of megestrol acetate in humans. , 1973, Acta endocrinologica.
[18] E. Coutinho. Clinical experience with implant contraception. , 1978, Contraception.
[19] P. Ebden,et al. Ectopic pregnancy with Implanon® , 2006, Journal of Family Planning and Reproductive Health Care.
[20] I. Sivin,et al. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. International Collaborative Post-Marking Surveillance. , 2001 .
[21] R. Sitruk-Ware,et al. Nestorone®: clinical applications for contraception and HRT , 2003, Steroids.
[22] D. Katz,et al. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus. , 1998, Fertility and sterility.
[23] E. Diczfalusy,et al. Facts about an implantable contraceptive: memorandum from a WHO meeting. , 1985, Bulletin of the World Health Organization.
[24] P. Morales,et al. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro. , 1987, Contraception.
[25] H. Croxatto,et al. Fertility control in women with a progestogen released in microquantities from subcutaneous capsules. , 1969, American journal of obstetrics and gynecology.
[26] J. Weikel,et al. Problems in evaluating chronic toxicity of contraceptive steroids in dogs. , 1977, Journal of toxicology and environmental health.
[27] K. Barnhart,et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). , 1997, Human reproduction.
[28] D. Lewis,et al. Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectable biodegradable contraceptive. , 1983, Biology of reproduction.
[29] H. C. Coelingh Bennink,et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. , 1999, Human reproduction.
[30] K. Fotherby. Potency and pharmacokinetics of gestagens. , 1990, Contraception.
[31] H. Croxatto,et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. , 2001, Contraception.
[32] B. Affandi. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. , 1998, Contraception.
[33] H. Croxatto,et al. Estradiol plasma levels during long-term treatment with Norplant subdermal implants. , 1988, Contraception.
[34] A. Meli,et al. MECHANISM BY WHICH 3-ENOL ETHERIFICATION ENHANCES THE ORAL ACTIVITY OF METHYLTESTOSTERONE IN RATS. , 1964, Endocrinology.
[35] S. Segal. The development of NORPLANT implants. , 1983, Studies in family planning.
[36] J. C. Stucki,et al. 6α-Methyl-17α-HYDROXYPROGESTERONE 17-ACYLATES; A NEW CLASS OF POTENT PROGESTINS1 , 1958 .
[37] Mike Grace,et al. One year on , 1999, British Dental Journal.
[38] J. Trussell,et al. Reducing unintended pregnancy in the United States. , 2008, Contraception.
[39] L. Mascarenhas. Insertion and removal of Implanon®: practical considerations , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[40] G. Benagiano,et al. Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 3. Factors affecting steroid diffusion in vivo and in vitro. , 1973, Acta endocrinologica.
[41] Horacio B Croxatt. Progestin implants for female contraception. , 2002, Contraception.
[42] S. Taneepanichskul,et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device. , 2000, Contraception.
[43] D. Wise,et al. Sustained release hormonal preparations for the delivery of fertility‐regulating agents , 2007 .
[44] G. Benagiano,et al. Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 2. Maintenance of ovarian function in patients with megestrol acetate implants. , 1973, Acta endocrinologica.
[45] E. Belsey. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. , 1988, Contraception.
[46] E. R. Garrett,et al. Evaluation, control, and prediction of drug diffusion through polymeric membranes. I. Methods and reproducibility of steady-state diffusion studies. , 1968, Journal of pharmaceutical sciences.
[47] A. Faúndes,et al. Transition from Norplant to Jadelle in a clinic with extensive experience providing contraceptive implants. , 2006, Contraception.
[48] P. Singh,et al. Two-year follow-up of changes in clinical chemistry in Singaporean Norplant acceptors: metabolic changes. , 1989, Contraception.
[49] I. Sivin,et al. Safety and Efficacy of Levonorgestrel Implant, Intrauterine Device, and Sterilization , 2001, Obstetrics and gynecology.
[50] C. G. Pitt,et al. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels. , 1983, American journal of obstetrics and gynecology.
[51] D. Mishell,et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. , 2001, Contraception.
[52] I. Sivin,et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. , 1998, Human reproduction.
[53] Odlind,et al. NORPLANT: biochemical effects. , 1983 .
[54] G. W. Anderson,et al. RACEMIZATION BY THE DICYCLOHEXYLCARBODIIMIDE METHOD OF PEPTIDE SYNTHESIS , 1958 .
[55] W. Ledger,et al. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres: phase II clinical study. , 1989, Fertility and sterility.
[56] J. Nassim. Women's bleeding patterns: ability to recall and predict menstrual events. World Health Organization Task Force on Psychosocial Research in Family, Planning, Special Programme of Research, Development and Research Training in Human Reproduction. , 1991, Studies in family planning.
[57] Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. , 2001, Contraception.
[58] D. Mishell,et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. , 2005, Contraception.
[59] S. Koide,et al. Nestorone®: a progestin with a unique pharmacological profile , 2000, Steroids.
[60] B. Chen,et al. A multicenter comparative clinical study of sino-levonorgestrel-releasing impants-No. I and No. II with Norplant. , 2004 .
[61] C. Bardin,et al. Clinical trial with 3-keto-desogestrel subdermal implants. , 1991, Contraception.
[62] S. Biswas,et al. Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants. , 2004, Contraception.
[63] H. Gabelnick,et al. Biodegradable systems for the sustained release of fertility-regulating agents. , 1979, Journal of steroid biochemistry.
[64] I. Sivin,et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls. , 1997, Contraception.
[65] I. Sivin,et al. Long-term contraception with a single implant of the progestin ST-1435. , 1981, Fertility and sterility.
[66] H. Croxatto,et al. The pharmacodynamics and efficacy of Implanon. An overview of the data. , 1998, Contraception.
[67] E. Coutinho,et al. Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. , 2006, Contraception.
[68] G. Benagiano,et al. Sustained release hormonal preparations. 5. Absorption of 6-methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione from polydimethylsiloxane implants in vivo. , 1970, Acta endocrinologica.
[69] V. Odlind,et al. Clinical results with subcutaneous implants containing 3-keto desogestrel. , 1990, Contraception.
[70] V. Odlind,et al. “Free Levonorgestrel Index” (FLI) is a better parameter than plasma level of levonorgestrel for predicting risk of pregnancy during use of subdermal contraceptive implants releasing levonorgestrel , 1988, Steroids.
[71] L. Mascarenhas,et al. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. , 1998, Human reproduction.
[72] S. Ratnam,et al. Implanon contraceptive implants: effects on carbohydrate metabolism. , 2001, Contraception.
[73] P. Kratochvíl,et al. Sustained release hormonal preparations. 6. Permeability constant of various steroids. , 1970, Steroids.
[74] R. Gurny,et al. Poly(ortho esters) - their development and some recent applications. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[75] E. Coutinho,et al. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). , 1993, Contraception.
[76] I. Sivin,et al. Jadelle Levonorgestrel Rod Implants: A Summary of Scientific Data and Lessons Learned from Programmatic Experience , 2002 .
[77] P. Vilja,et al. Norplant implants: the mechanism of contraceptive action. , 1991, Fertility and sterility.
[78] Darney Pd,et al. Sustained-release contraceptives. , 1990 .